Human Papillomavirus (HPV) Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Human Papillomavirus (HPV) Vaccines Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Human Papillomavirus (HPV) Vaccines market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Human Papillomavirus (HPV) Vaccines market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Human Papillomavirus (HPV) Vaccines Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Human Papillomavirus (HPV) Vaccines Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Human Papillomavirus (HPV) Vaccines Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Merck & Co., Inc and GlaxoSmithKline plc to Rule the HPV Market
The human papillomavirus vaccine market is dominated by Merck Co., Inc and GlaxoSmithKline plc due to their only products available in the market for the treatment of HPV infections. Also, the implementation of key distribution strategy in the developed as well as in developing nations has led to an increase in sales of the two companies. Merck has a strong portfolio of HPV vaccines that includes Gardasil and Gardasil 9. Likewise, Merck Co., Inc also has an effective HPV vaccine portfolio in competition to GSKs portfolio. The companys top-selling vaccines Gardasil and Gardasil 9, are contributing to the leading position of Merck.

Moreover, the companies are focused on launching novel vaccines in the market against different strains of human papillomavirus. Currently, Merck has three pipeline candidates in phase 3, while GSK has two pipeline candidates undergoing clinical trials.
List Of Key Companies Covered:

GlaxoSmithKline plc.
Merck & Co., Inc

REPORT COVERAGE

As human papillomavirus infection is the most common sexually transmitted disease worldwide demand for HPV vaccines has tremendously increased. The imbalance between the supply-demand has currently caused a hindrance to the growth of the market. Furthermore, increasing prevalence of HPV associated cancer is also a major reason in pushing forward the demand for HPV vaccines. But, later in the upcoming years, the market is anticipated to witness a stellar growth owing to large HPV vaccines sales, the introduction of vaccines in lower-income countries, and due to increasing rates of HPV infections.

Along with this, the report provides a detailed analysis of the human papillomavirus vaccine market and focuses on the key aspects such as leading companies, product types, and leading applications of the product. Besides, the report offers insights into the market trends and highlights key industry developments. In addition to the features above, the report encompasses several factors that have contributed to the growth of the market over the recent years. Furthermore, it offers a detailed analysis and information as per market segments, helping our readers to get a comprehensive overview of the global market.
Report Scope & Segmentation

 Segmentation

By Type

  
Bivalent
  
Polyvalent

By Disease Indication

  
HPV Associated Cancer
  
Genital Warts

By Distribution Channel

  
Hospitals & Retail Pharmacies
  
Government Suppliers
  
Others

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America)
  
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

INDUSTRY DEVELOPMENT:

September 2019: GlaxoSmithKline and china-based company Xiamen Innovax Biotech entered into a partnership for the development and commercialization of next-generation HPV vaccines.

April 2019: DNA-based immunotherapy VGX-300 of Inovio Pharmaceuticals, Inc. was selected as the Best Therapeutic Vaccine at the World Vaccine Congress. VGX-300 is under investigation for treatment of HPV16 and HPV18 infections.